Business
Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is
About this update from Vir Biotechnology, Inc.
[{"type":"text","content":" SAN FRANCISCO--(BUSINESS WIRE)--\nVir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, at 1:50 p.m. PT / 4:50 p.m. ET in New York City.\n\n\nA live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days.\n\n\nAbout Vir Biotechnology, Inc.\n\n\nVir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Vir’s clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections, in addition to multiple oncology programs. Vir also has a preclinical portfolio of programs across a range of other infectious diseases and oncologic malignancies. Vir routinely posts information that may be important to investors on its website.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240822961651/en/\n\nMedia\nArran Attridge\nSenior Vice President, Corporate Communications\[email protected]\n\n\nInvestors\nRichard Lepke\nSenior Director, Investor Relations\[email protected]\n\n\nSource: Vir Biotechnology, Inc.","length":2874,"tagName":"div"}]